Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus MD 76R.
HYPAQUE-M,90% vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Terminal half-life 1-2 hours; prolonged in renal impairment.
Renal: >95% unchanged; biliary/fecal: <5%
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent